The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

Martin Stangel, Sten Fredrikson, Edgar Meinl, Axel Petzold, Olaf Stüve, Hayrettin Tumani

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Diagnosis of multiple sclerosis (MS) requires the exclusion of other possible diagnoses. For this reason, the cerebrospinal fluid (CSF) should be routinely analysed in patients with a first clinical event suggestive of MS. CSF analysis is no longer mandatory for diagnosis of relapsing-remitting MS, as long as MRI diagnostic criteria are fulfilled. However, caution is required in diagnosing MS in patients with negative MRI findings or in the absence of CSF analysis, as CSF investigation is useful to eliminate other causes of disease. The detection of oligoclonal IgG bands in CSF has potential prognostic value and is helpful for clinical decision-making. In addition, CSF analysis is important for research into the pathogenesis of MS. Pathophysiological and neurodegenerative findings of inflammation in MS have been derived from CSF investigations. Novel CSF biomarkers, though not yet validated, have been identified for diagnosis of MS and for ascertaining disease activity, prognosis and response to treatment, and are likely to increase in number with modern detection techniques. In this Review, we summarize CSF findings that shed light on the differential diagnosis of MS, and highlight the potential of novel biomarkers for this disease that could advance understanding of its pathophysiology.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalNature Reviews Neurology
Volume9
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Multiple Sclerosis
Cerebrospinal Fluid
Oligoclonal Bands
Biomarkers
Relapsing-Remitting Multiple Sclerosis
Differential Diagnosis
Inflammation
Research

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. / Stangel, Martin; Fredrikson, Sten; Meinl, Edgar; Petzold, Axel; Stüve, Olaf; Tumani, Hayrettin.

In: Nature Reviews Neurology, Vol. 9, No. 5, 05.2013, p. 267-276.

Research output: Contribution to journalArticle

Stangel, Martin ; Fredrikson, Sten ; Meinl, Edgar ; Petzold, Axel ; Stüve, Olaf ; Tumani, Hayrettin. / The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. In: Nature Reviews Neurology. 2013 ; Vol. 9, No. 5. pp. 267-276.
@article{90174577126e42908c3ed2eaa1c96f28,
title = "The utility of cerebrospinal fluid analysis in patients with multiple sclerosis",
abstract = "Diagnosis of multiple sclerosis (MS) requires the exclusion of other possible diagnoses. For this reason, the cerebrospinal fluid (CSF) should be routinely analysed in patients with a first clinical event suggestive of MS. CSF analysis is no longer mandatory for diagnosis of relapsing-remitting MS, as long as MRI diagnostic criteria are fulfilled. However, caution is required in diagnosing MS in patients with negative MRI findings or in the absence of CSF analysis, as CSF investigation is useful to eliminate other causes of disease. The detection of oligoclonal IgG bands in CSF has potential prognostic value and is helpful for clinical decision-making. In addition, CSF analysis is important for research into the pathogenesis of MS. Pathophysiological and neurodegenerative findings of inflammation in MS have been derived from CSF investigations. Novel CSF biomarkers, though not yet validated, have been identified for diagnosis of MS and for ascertaining disease activity, prognosis and response to treatment, and are likely to increase in number with modern detection techniques. In this Review, we summarize CSF findings that shed light on the differential diagnosis of MS, and highlight the potential of novel biomarkers for this disease that could advance understanding of its pathophysiology.",
author = "Martin Stangel and Sten Fredrikson and Edgar Meinl and Axel Petzold and Olaf St{\"u}ve and Hayrettin Tumani",
year = "2013",
month = "5",
doi = "10.1038/nrneurol.2013.41",
language = "English (US)",
volume = "9",
pages = "267--276",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

AU - Stangel, Martin

AU - Fredrikson, Sten

AU - Meinl, Edgar

AU - Petzold, Axel

AU - Stüve, Olaf

AU - Tumani, Hayrettin

PY - 2013/5

Y1 - 2013/5

N2 - Diagnosis of multiple sclerosis (MS) requires the exclusion of other possible diagnoses. For this reason, the cerebrospinal fluid (CSF) should be routinely analysed in patients with a first clinical event suggestive of MS. CSF analysis is no longer mandatory for diagnosis of relapsing-remitting MS, as long as MRI diagnostic criteria are fulfilled. However, caution is required in diagnosing MS in patients with negative MRI findings or in the absence of CSF analysis, as CSF investigation is useful to eliminate other causes of disease. The detection of oligoclonal IgG bands in CSF has potential prognostic value and is helpful for clinical decision-making. In addition, CSF analysis is important for research into the pathogenesis of MS. Pathophysiological and neurodegenerative findings of inflammation in MS have been derived from CSF investigations. Novel CSF biomarkers, though not yet validated, have been identified for diagnosis of MS and for ascertaining disease activity, prognosis and response to treatment, and are likely to increase in number with modern detection techniques. In this Review, we summarize CSF findings that shed light on the differential diagnosis of MS, and highlight the potential of novel biomarkers for this disease that could advance understanding of its pathophysiology.

AB - Diagnosis of multiple sclerosis (MS) requires the exclusion of other possible diagnoses. For this reason, the cerebrospinal fluid (CSF) should be routinely analysed in patients with a first clinical event suggestive of MS. CSF analysis is no longer mandatory for diagnosis of relapsing-remitting MS, as long as MRI diagnostic criteria are fulfilled. However, caution is required in diagnosing MS in patients with negative MRI findings or in the absence of CSF analysis, as CSF investigation is useful to eliminate other causes of disease. The detection of oligoclonal IgG bands in CSF has potential prognostic value and is helpful for clinical decision-making. In addition, CSF analysis is important for research into the pathogenesis of MS. Pathophysiological and neurodegenerative findings of inflammation in MS have been derived from CSF investigations. Novel CSF biomarkers, though not yet validated, have been identified for diagnosis of MS and for ascertaining disease activity, prognosis and response to treatment, and are likely to increase in number with modern detection techniques. In this Review, we summarize CSF findings that shed light on the differential diagnosis of MS, and highlight the potential of novel biomarkers for this disease that could advance understanding of its pathophysiology.

UR - http://www.scopus.com/inward/record.url?scp=84877582501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877582501&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2013.41

DO - 10.1038/nrneurol.2013.41

M3 - Article

C2 - 23528543

AN - SCOPUS:84877582501

VL - 9

SP - 267

EP - 276

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 5

ER -